{"transactions":[{"id":715321,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":32141,"kind":"person","name":"Malkani Dhiraj H","position":1,"cik":"0002143491","reported_name":"Malkani Dhiraj H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF STRATEGY OFFICER"}}],"security":"Performance Share Unit","published_at":"2026-07-06T20:42:47.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":1307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance"},{"field":"shares","element":"transactionShares","label":"F4","text":"The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1307},"source":{"system":"sec-edgar","filing":"0002143491-26-000004","document":"form4-07062026_080742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000214349126000004/form4-07062026_080742.xml","form_type":"4"}},{"id":715320,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":32141,"kind":"person","name":"Malkani Dhiraj H","position":1,"cik":"0002143491","reported_name":"Malkani Dhiraj H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF STRATEGY OFFICER"}}],"security":"Performance Share Unit","published_at":"2026-07-06T20:42:47.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":1245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance"},{"field":"shares","element":"transactionShares","label":"F4","text":"The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The PSUs shall vest, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The PSUs shall vest, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1245},"source":{"system":"sec-edgar","filing":"0002143491-26-000004","document":"form4-07062026_080742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000214349126000004/form4-07062026_080742.xml","form_type":"4"}},{"id":715319,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":32141,"kind":"person","name":"Malkani Dhiraj H","position":1,"cik":"0002143491","reported_name":"Malkani Dhiraj H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF STRATEGY OFFICER"}}],"security":"Performance Share Option","published_at":"2026-07-06T20:42:47.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":2188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The PSOs shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."}],"balance_after":0,"derivative":{"exercise_price":62.88,"expiration_date":"2036-06-30","underlying":"Class A Ordinary Share","underlying_shares":2188},"source":{"system":"sec-edgar","filing":"0002143491-26-000004","document":"form4-07062026_080742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000214349126000004/form4-07062026_080742.xml","form_type":"4"}},{"id":715318,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":32141,"kind":"person","name":"Malkani Dhiraj H","position":1,"cik":"0002143491","reported_name":"Malkani Dhiraj H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF STRATEGY OFFICER"}}],"security":"Performance Share Option","published_at":"2026-07-06T20:42:47.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":2119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Performance Share Options (PSO) shall vest and become exercisable, if at all, upon the submission to the U.S. Food and Drug Administration (the \"FDA\") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions."}],"balance_after":0,"derivative":{"exercise_price":62.88,"expiration_date":"2036-06-30","underlying":"Class A Ordinary Share","underlying_shares":2119},"source":{"system":"sec-edgar","filing":"0002143491-26-000004","document":"form4-07062026_080742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000214349126000004/form4-07062026_080742.xml","form_type":"4"}},{"id":715317,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":32141,"kind":"person","name":"Malkani Dhiraj H","position":1,"cik":"0002143491","reported_name":"Malkani Dhiraj H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF STRATEGY OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-07-06T20:42:47.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, July 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, July 1, 2026."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0002143491-26-000004","document":"form4-07062026_080742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000214349126000004/form4-07062026_080742.xml","form_type":"4"}},{"id":715316,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":32141,"kind":"person","name":"Malkani Dhiraj H","position":1,"cik":"0002143491","reported_name":"Malkani Dhiraj H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF STRATEGY OFFICER"}}],"security":"Share Option","published_at":"2026-07-06T20:42:47.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":82600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is July 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":62.88,"expiration_date":"2036-06-30","underlying":"Class A Ordinary Share","underlying_shares":82600},"source":{"system":"sec-edgar","filing":"0002143491-26-000004","document":"form4-07062026_080742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000214349126000004/form4-07062026_080742.xml","form_type":"4"}}]}